Callan Family Office LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Callan Family Office LLC purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, Holdings Channel.com reports. The fund purchased 1,042 shares of the biopharmaceutical company’s stock, valued at approximately $245,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Allworth Financial LP grew its position in shares of Alnylam Pharmaceuticals by 6.8% during the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 38 shares in the last quarter. Nixon Peabody Trust Co. grew its position in shares of Alnylam Pharmaceuticals by 1.9% during the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 43 shares in the last quarter. Huntington National Bank grew its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares in the last quarter. IFP Advisors Inc grew its position in shares of Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 47 shares in the last quarter. Finally, Nwam LLC grew its position in shares of Alnylam Pharmaceuticals by 5.8% during the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 50 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ALNY. Morgan Stanley boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Finally, Sanford C. Bernstein lowered their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $304.26.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,986 shares of company stock valued at $20,397,849. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 2.4 %

Alnylam Pharmaceuticals stock opened at $238.74 on Wednesday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm has a market capitalization of $30.91 billion, a price-to-earnings ratio of -110.02 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock’s fifty day moving average is $254.64 and its two-hundred day moving average is $260.93.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.